Augmentation of donor bone marrow engraftment in histoincompatible XXXX recipients by granulocyte/macrophage colony-stimulating factor.

@entity1 @entity2304 @entity2132 @entity19
T cell depletion of donor bone marrow can prevent @entity2132 ( @entity2132 ) in @entity1 and @entity19 marrow graft recipients. However, engraftment in the recipient may be compromised as a consequence of donor marrow T cell depletion. The effect of recombinant @entity19 granulocyte/macrophage colony-stimulating factor (rmu @entity2304 ) on engraftment and hematologic reconstitution was evaluated in a @entity19 allogeneic bone marrow transplantation (BMT) model involving T cell depletion of marrow. Before transplantation into irradiated @entity19 differing at major and minor histocompatibility loci, rmu @entity2304 was preincubated with T cell-depleted donor marrow. When low degrees of engraftment were noted in control recipients, treatment of donor marrow with high concentrations of rmu @entity2304 led to enhanced engraftment. Ex vivo donor graft incubation with rmu @entity2304 or a single in vivo injection of rmu @entity2304 were both effective means of promoting engraftment. When the engraftment rate in control recipients was high, rmu @entity2304 did not have an identifiable effect. Only slight increases in hematologic recovery were detected regardless of the rate of engraftment. Neither post-BMT survival nor marrow stem cell capacity was affected by rmu @entity2304 incubation. Furthermore, growth factor administration did not have a significant effect on the incidence of @entity2132 in recipients of non-T cell-depleted bone marrow splenocyte preparations. In vitro natural killer-mediated target cell lysis was not altered by incubation of effector cells with rmu @entity2304 . These results demonstrate the potential of ex vivo rmu @entity2304 treatment of donor marrow to facilitate engraftment across extensive histo-compatibility barriers.
